Theravance Biopharma (TBPH) Current Deferred Revenue (2013 - 2023)

Theravance Biopharma (TBPH) has reported Current Deferred Revenue for 11 consecutive years, with $24000.0 the latest figure, recorded in Q3 2023.

• In Q3 2023, Current Deferred Revenue changed 0.0% year-over-year to $24000.0; the TTM figure through Sep 2023 stood at $24000.0 (changed 0.0% YoY), while the FY2022 annual figure was $24000.0, down 75.51% from the prior year.
• Current Deferred Revenue held at $24000.0 in Q3 2023 per TBPH's latest filing, from $24000.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $43.3 million in Q2 2019 and bottomed at $24000.0 in Q2 2022.
• Historically, Current Deferred Revenue has averaged $12.9 million across 5 years, with a median of $5.7 million in 2021.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue sank 99.58% — and 2023, when it changed 0.0%.
• Theravance Biopharma's Current Deferred Revenue stood at $31.6 million in 2019, then slumped by 63.51% to $11.5 million in 2020, then plunged by 99.15% to $98000.0 in 2021, then slumped by 75.51% to $24000.0 in 2022, then changed by 0.0% to $24000.0 in 2023.
• Business Quant data shows TBPH's Current Deferred Revenue at $24000.0 in Q3 2023, $24000.0 in Q2 2023, and $24000.0 in Q1 2023.